India Drug Authorities To Review Suspension Of Three Popular Drugs
This article was originally published in PharmAsia News
India drug regulators plan a review of the controversial decision to suspend the manufacturing and marketing of Takeda’s off-patent Actos (pioglitazone), Lundbeck’s Deanxit (flupentixol/melitracen), and Analgin (metamizole) in response to reports of adverse effects.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.